Sareum Holdings PLC

Receive alerts
Market Cap:
£11.06 m
52 weeks high
52 weeks low

Viewing results 1-25 of 100


Sierra Oncology still seeking further funding for Sareum Holdings's Chk1 inhibitor

Sareum is eligible to receive 27.5% of a US$7.5mln milestone payment upon the dosing of the first patient in the first Phase 1 trial of SRA737 in the United States, and a payment of US$12mln upon the dosing of the first patient of a randomized Phase 2 trial...

1 week, 6 days ago

Sareum notes decision by Sierra Oncology to explore options for future development of SRA737

SRA737 is a checkpoint kinase 1 that Sierra licensed from Sareum back in 2016...

on 27/6/19

Sareum raises £680k as it looks to take its TYK2/JAK1 inhibitors into the clinic next year

Sareum raised the money by selling 170.37mln new shares at 0.4p each – a 25% discount to Tuesday’s closing price...

on 26/6/19

Sareum surges as it signals progress on pre-clinical programmes

"The potential for our two preclinical TYK2/JAK1 inhibitors in autoimmune diseases and cancer is gaining increasing clinical validation and we are convinced that SDC-1801 and SDC-1802 represent strong and well-differentiated candidates to address diseases within these areas," said Dr Tim Mitchell, the Sareum CEO. ...

on 13/6/19

Sareum Holdings hails early-stage efficacy data for cancer drug

The latest update was provided at a America's largest and most prestigious cancer conference ...

on 3/6/19
Retail & consumer

Immuno-oncology: All you wanted to know but were too afraid to ask

Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers...

on 27/5/19

Sareum Holdings created drug to be showcased at leading cancer event next month

Sareum's partner Sierra Oncology has provided the essence of what it will share with delegates at the upcoming American Society of Clinical Oncology in Chicago...

on 16/5/19

Sareum Holdings jumps as it says new data on cancer drug to be released at top conference

The update is being presented in the form of two abstracts at the American Society of Clinical Oncology in Chicago ...

on 23/4/19

Sareum’s flagship Chk1 inhibitor shows serious lung cancer potential in mouse models

After 50 days, eight out of ten mice achieved a complete response, which means there was no detectable sign of cancer anymore...

on 2/4/19

Sareum boss “very pleased” with progress of flagship Chk1 inhibitor

US firm Sierra Oncology has licensed the molecule and the results from two early-stage ovarian cancer studies are due in the current half...

on 4/3/19

Sareum surges as its flagship Chk1 inhibitor continues to produce encouraging data

Researchers in Texas found that SRA737, when combined with immunotherapy and low dose gemcitabine, had a “dramatic enhancement” in anti-tumour activity...

on 28/2/19

Sareum Holdings primed for progress

Dr Tim Mitchell, chief executive of Sareum, said he believes there is a "clear opportunity to generate significant value for our shareholders over the next 12 months"...

on 22/2/19

Sareum Holdings shares soar as Hybridan spotlights read-across from big US pharma takeover deal

The small-cap broker’s analysts noted that Bristol-Myers Squibb has agreed to acquire Celgene for US$74bn, with the combined entity to have six expected near-term product launches...

on 3/1/19

Sareum Holdings chairman says drug discovery group is making progress

At the company’s annual meeting, being held in the City of London, chairman Dr Stephen Parker will point to the progress of SRA737, which has been licensed to Sierra Oncology ...

on 18/12/18

Sareum’s SRA737 Chk1 inhibitor impresses once again

Sierra Oncology, the US firm which is licensing Sareum’s SRA737 compound, published more data overnight...

on 30/11/18

Latest data suggests Sareum’s SRA737 Chk1 inhibitor has potential in ovarian cancer

Data presented at a cancer convention in Dublin suggested SRA737 showed “promising efficacy” in pre-clinical models of high-grade serous ovarian cancer ...

on 15/11/18

Preliminary results from Sierra Oncology’s clinical trials of Sareum’s SRA737 compound due in H1 2019

US firm Sierra Oncology, which is the licence holder of SRA737, said in its quarterly update, it has made “substantial progress” with its two clinical development programmes for the compound...

on 8/11/18

Sareum secures funding for drug programme

The company has raised £850,000 before expenses, which will be used to develop potential treatments for cancer and autoimmune diseases ...

on 26/10/18

Sareum selects potential anti-cancer molecule for further development

Sareum has now chosen two molecules from its TYK2 inhibitor programme for further development, one as a potential treatment for autoimmune disease and the other for certain types of cancer...

on 26/9/18

Sareum reports “strong progress” made with in-house and out-licensed drug programmes

Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme...

on 11/9/18

Sareum to further develop ‘potential best-in-class’ autoimmune disease treatment

Sareum thinks SDC-1801 is the most potent in the series of compounds and will now take it through pre-clinical development before advancing into human trials, which could begin as early as 2020...

on 10/9/18

Sareum Holdings investors receive update on progress of cancer drug

SRA737 is a checkpoint kinase-1 inhibitor, one of a new breed of treatments...

on 9/8/18